Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$-0.46
EPS est.
—
EPS surprise
—
1-day move
+13.66%
Zai Lab Limited reported an EPS of $-0.46, which did not meet any consensus expectations. Despite this, the stock rose by 13.66%, indicating that investors may be optimistic about future prospects or other underlying factors not detailed in the earnings call.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.46 | N/A | — |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.
Zai Lab Limited is a biotechnology company focused on developing innovative medicines to address unmet medical needs in the healthcare sector. With a market cap of $3 billion, it plays a critical role in advancing treatments for various diseases, which is particularly important as the demand for new therapies continues to grow.
Last quarter
In the last quarter, Zai Lab reported an EPS of -$0.46, which was better than the expected -$0.58, resulting in a positive surprise. However, the stock dropped by nearly 6% the following day, indicating mixed investor sentiment.
EPS beat streak
0Q
EPS beat rate
50%
Avg EPS surprise
+3.86%
Avg 1-day reaction
-1.93%
Overall expectations for Zai Lab's upcoming earnings are uncertain, given the lack of analyst estimates and management guidance. Investors are particularly focused on the company's ability to manage costs and drive revenue growth.
Bull case
If Zai Lab can demonstrate strong revenue growth and effective cost management, it could signal a turnaround and boost investor confidence in its future prospects.
Bear case
Conversely, if the company fails to show progress in its drug development pipeline or reports higher-than-expected losses, it could lead to further declines in stock price.
The print will turn on these.
Q1
What will be the reported EPS for this quarter?
The EPS figure will be crucial in assessing the company's profitability and could significantly impact investor sentiment.
Q2
How much has Zai Lab invested in R&D this quarter?
Investments in R&D are vital for the company's future growth, and any changes could indicate shifts in strategy or product development timelines.
—
Est. EPS
$0.11
Est. Rev
$4.8B
Impl. Move
±18.7%
Why consensus could be wrong
The Street may be underestimating the potential for Zai Lab to improve its EPS significantly this quarter, given its recent positive surprise trends.
Supporting evidence
Zai Lab has a 50% EPS beat rate in the last eight quarters, indicating potential for positive surprises.
Despite recent losses, the company has shown resilience in managing costs effectively.
Options pricing suggests a significant move, indicating that traders expect volatility which could favor a positive outcome.
Key risk
If the EPS comes in better than -$0.40, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around whether Zai Lab can improve its financial performance and effectively manage its R&D investments.
Bull confirmed if
A reported EPS of -$0.40 or better would confirm the bull case and suggest improved profitability.
Bear confirmed if
An EPS worse than -$0.50 would confirm the bear case and raise concerns about the company's financial health.
What the market is pricing for the move.
Implied Move
±32.08%
Historical Avg
±6.4%
The options market is pricing in a significant move of over 32%, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±32.1% while ZLAB has averaged ±6.4% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
60.2%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Zai Lab beats expectations, history suggests the stock could rise by around 5.5% on the first day, confirming a positive outlook.
In line / cautious
If results are in line with expectations but management provides cautious commentary, the stock may see a muted reaction as investors reassess their outlook.
Miss
Should the company miss expectations, history suggests a potential decline of about 1.1%, as investors react negatively to disappointing results.
The lines on the call that would change the story.